Course Overview


This Course reviews the different types of glucose-lowering medicines that are currently used to treat type 2 diabetes mellitus.

Learning Outcomes

  • Correlate the indications for starting, increasing or decreasing a medicine with individual patient characteristics to enhance individuality of treatment
  • Differentiate between each class of non-insulin, glucose-lowering medication to select the most appropriate treatment for patients
  • Identify the contraindications and potential adverse reactions of each class of medications in order to prevent adverse patient outcomes

Topics include:

  • Biguanides and Sulfonylureas
  • Alpha-glucosidase Inhibitor (AGI) and Thiazolidinediones (TZDs)
  • Glucagon-like peptide 1 analogues (GLP-1s)
  • Dipeptidyl peptidase-4 Inhibitors (DPP-4s)
  • Sodium Glucose Transporter-2 Inhibitors (SGLT-2s)
  • Where does that leave insulin?

Target audience

All health professionals caring for individuals with type 2 diabetes mellitus.


To enhance knowledge of diabetes management by reviewing current medicines used in the treatment of people with type 2 diabetes mellitus.


Type 2 diabetes is the most common form of diabetes in Australia (85–90%) and its incidence is increasing worldwide, with more and more younger people now becoming affected. Whilst some of the management of this chronic disease may be initially possible through changes to lifestyle, treatment with medication is usually required. Health professionals need to remain up-to-date regarding the types of medications prescribed for this disease, as these types of medications are constantly changing. Understanding of how these medicines work, their side effects, and contraindications is imperative in order to promote positive patient outcomes.

Health professionals in Australia that are registered with AHPRA are required to obtain continuing professional development (CPD) hours/points each year that relates to their context of practice, in order to comply with mandatory regulatory requirements.